Call for Papers: International Conference on Nanotechnologies and Biomedical Engineering (ICNBME)

7 - 8 July 2011, Chisinau, Republic of Moldova.
ICNBME-2011 continues the series of International Conferences in the field of nanotechnologies and biomedical engineering. The conference aims at bringing together scientists and engineers dealing with fundamental and applied research for reporting on the latest theoretical developments and applications in the fields involved.

Contributing papers are called in the following areas:

  • Nanotechnologies and Nanomaterials;
  • Micro- and Nano-objects, Nanostructured and highly integrated systems, Biophysics;
  • Plasmonics and Metamaterials;
  • Biomedical Optics and Lasers;
  • Sensors and Transducers;
  • Terahertz spectroscopy;
  • Biomedical Instrumentation and Devices;
  • Health Care Management;
  • Medical Imaging, Image and Signal Processing;
  • Radiation Protection and Dosymetry, Biological Effect of Radiation;
  • Biomedical Engineering Education;
  • Information Technologies for Health Care, Telemedicine and E-Health;
  • Other topics in biomedical engineering.

Submission of Papers
Contributed papers should be subscribed on four-six pages and submitted by e-mail in Microsoft Word format to This email address is being protected from spambots. You need JavaScript enabled to view it.

Accepted papers will be included in the Conference Proceedings, distributed to the participants at the beginning of the conference.

Deadlines:

  • May 1 st, 2011 - Submission of extended abstracts
  • May 15th, 2011 - Notification of acceptance
  • June 15th, 2011 - Advanced Conference Registration
  • June 20th, 2011 - Hotel/trip reservation
  • July 1th, 2011 --Deadline for Registration Fee refunding
  • July 5-6th, 2011 - Arrival and Registration of Participants
  • July 7th, 2011 - Opening of the Conference
  • July 9 th, 2011 - Social Program
  • July 9-10th, 2011 - Departure of Participants

For further information and registration, please visit:
http://www.icnbme.sibm.md

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...